Mainz Biomed BV (MYNZ) - Total Assets
Based on the latest financial reports, Mainz Biomed BV (MYNZ) holds total assets worth $5.33 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mainz Biomed BV - Total Assets Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's total assets have evolved over time, based on quarterly financial data. Also see MYNZ market cap overview for the company's overall valuation and market capitalisation.
Mainz Biomed BV - Asset Composition Analysis
Current Asset Composition (December 2025)
Mainz Biomed BV's total assets of $5.33 Million consist of 34.6% current assets and 65.4% non-current assets. Review Mainz Biomed BV (MYNZ) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.7% |
| Accounts Receivable | $110.89K | 2.1% |
| Inventory | $216.89K | 4.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.11 Million | 20.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Mainz Biomed BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Mainz Biomed BV share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mainz Biomed BV's current assets represent 34.6% of total assets in 2025, a decrease from 36.3% in 2019.
- Cash Position: Cash and equivalents constituted 16.7% of total assets in 2025, down from 28.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 20.9% of total assets.
Mainz Biomed BV Competitors by Total Assets
Key competitors of Mainz Biomed BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
Mainz Biomed BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.50 | 1.32 | 0.27 |
| Quick Ratio | 0.44 | 1.26 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.85 Million | $1.89 Million | $-515.56K |
Mainz Biomed BV - Advanced Valuation Insights
This section examines the relationship between Mainz Biomed BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.53 |
| Latest Market Cap to Assets Ratio | 1.78 |
| Asset Growth Rate (YoY) | -59.8% |
| Total Assets | $5.33 Million |
| Market Capitalization | $9.49 Million USD |
Valuation Analysis
Above Book Valuation: The market values Mainz Biomed BV's assets above their book value (1.78x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Mainz Biomed BV's assets decreased by 59.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mainz Biomed BV (2019–2025)
The table below shows the annual total assets of Mainz Biomed BV from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.33 Million | -59.76% |
| 2024-12-31 | $13.24 Million | -14.09% |
| 2023-12-31 | $15.41 Million | -23.87% |
| 2022-12-31 | $20.24 Million | +101.59% |
| 2021-12-31 | $10.04 Million | +1391.35% |
| 2020-12-31 | $673.27K | -5.96% |
| 2019-12-31 | $715.96K | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more